The Journal of dermatological treatment
-
Review
Risk of herpes zoster with IL-17 inhibitor therapy for psoriasis and other inflammatory conditions.
Background: Psoriasis is a chronic inflammatory skin disease that has been associated with a significantly higher risk of herpes zoster (HZ). Several newer biologics such as secukinumab, ixekizumab, and brodalumab inhibit IL-17 and have been highly effective for treatment of psoriasis. However, adverse events related to the immunosuppressive properties of these biologics have been observed. ⋯ Conclusion: IL-17 inhibitors do not appear to increase risk of HZ. However, IL-17 inhibitors are relatively new medications, and further long-term data may be necessary to confirm this finding. Nevertheless, HZ vaccination should be considered on a case-bycase basis prior to initiating IL-17 therapy.
-
YouTube is becoming an increasingly popular resource for patients seeking knowledge regarding treatment options for dermatologic conditions. This study assessed the quality of content on YouTube regarding topical treatment for psoriasis. A cross-sectional analysis of YouTube videos was conducted using search terms related to psoriasis topical therapies. ⋯ Videos criticizing medically-prescribed therapies and consultations with healthcare providers had significantly more views than those encouraging seeking medical expertise. Overall, YouTube videos about topical treatment options for psoriasis largely favor natural treatments over medical recommendations and discourage seeking medical advice. Dermatologists should consider posting information to YouTube to increase the volume of evidence-based, patient-directed material available through this platform.
-
The COVID-19 pandemic has greatly impacted dermatology clinical trial operations due to mandated governmental and institutional shut-downs and newly implemented restrictions. During this unprecedented time, measures should be taken to maintain research conduct compliance while also ensuring the safety of trial staff and participants. Herein, we underscore the challenges facing dermatology trials during the COVID-19 pandemic, and offer strategies to maintain compliant and safe conduct.